Adenosine

Adenosine

SCHEMBL1858293

NC(CC(=O)O)C(=O)O.Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O

nearest known ligand 0.77

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADORA1ADORA2AADORA2BADORA3

The experimentally established mechanism targets of Adenosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 known ✓ P0DMS8 1/20 0.77
ADORA2A known ✓ P29274 1/20 0.77
ADORA2B known ✓ P29275 1/20 0.77
ADORA1 known ✓ P30542 1/20 0.77
DOT1L Q8TEK3 6/20 0.77
KMT2A Q03164 2/20 0.77
DPP4 P27487 1/20 0.77
MEN1 O00255 1/20 0.77
SLC28A1 O00337 1/20 0.77
MAP3K7 O43318 1/20 0.77
SLC28A2 O43868 1/20 0.77
GAPDH P04406 1/20 0.77
MAPK1 P28482 1/20 0.77
STAT6 P42226 1/20 0.77
PI4KA P42356 1/20 0.77
SMN1; SMN2 Q16637 1/20 0.77
PI4K2B Q8TCG2 1/20 0.77
SLC29A1 Q99808 1/20 0.77
PI4K2A Q9BTU6 1/20 0.77
SLC28A3 Q9HAS3 1/20 0.77

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Adenosine SCHEMBL28045831 0.91 DOT1L (0.78) DOT1LKMT2ADPP4MEN1SLC28A1
Adenosine SCHEMBL29233226 0.90 EHMT2 (0.75) DOT1LKMT2ADPP4MEN1SLC28A1
Adenosine SCHEMBL27579066 0.90 NNMT (0.77) DOT1LKMT2ADPP4MEN1SLC28A1
Adenosine SCHEMBL6408986 0.89 NNMT (0.76) DOT1LKMT2ADPP4MEN1SLC28A1
Adenosine SCHEMBL6408967 0.89 NNMT (0.76) DOT1LKMT2ADPP4MEN1SLC28A1
Adenosine SCHEMBL2985961 0.89 ADORA3 (0.85) DOT1LKMT2ADPP4MEN1SLC28A1
Adenosine SCHEMBL9295609 0.89 ADORA3 (0.85) DOT1LKMT2ADPP4MEN1SLC28A1
Adenosine SCHEMBL9426528 0.89 ADORA3 (0.89) DOT1LKMT2ADPP4MEN1SLC28A1
Adenosine SCHEMBL31364221 0.88 DOT1L (0.83) DOT1LKMT2ADPP4MEN1SLC28A1
Adenosine SCHEMBL4401875 0.88 ADORA3 (0.87) DOT1LKMT2ADPP4MEN1SLC28A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160120894-A1 USE OF ADENOSINE ASPARTATE IN THE DIFFERENTIAL ACTIVATION OF MACROPHAGES IN INFLAMMATORY-FIBROGENIC PROCESSES AND ITS REVERSAL UNIVERSIDAD NACIONAL AUTONOMA DE MEXICO (MX) 2016-05-05 US claimed
US-8507459-B2 Use of adenosine aspartate for the preparation of pharmaceutical products for the treatment of liver cancer UNIVERSIDAD NACIONAL AUTONNOMA DE MEXICO (MX) 2013-08-13 US claimed
US-20110105425-A1 USE OF ADENOSINE ASPARTATE FOR THE PREPARATION OF PHARMACEUTICAL PRODUCTS FOR THE TREATMENT OF LIVER CANCER UNIVERSIDAD NACIONAL AUTONOMA DE MEXICO (MX) 2011-05-05 US claimed
EP-2186519-A1 USE OF ADENOSINE ASPARTATE FOR THE PREPARATION OF PHARMACEUTICAL PRODUCTS FOR THE TREATMENT OF LIVER CANCER UNIVERSIDAD NACIONAL AUTONOMA DE MEXICO (MX) 2010-05-19 EP claimed
US-20160120894-A1 USE OF ADENOSINE ASPARTATE IN THE DIFFERENTIAL ACTIVATION OF MACROPHAGES IN INFLAMMATORY-FIBROGENIC PROCESSES AND ITS REVERSAL UNIVERSIDAD NACIONAL AUTONOMA DE MEXICO (MX) 2016-05-05 US disclosed
US-20160120894-A1 USE OF ADENOSINE ASPARTATE IN THE DIFFERENTIAL ACTIVATION OF MACROPHAGES IN INFLAMMATORY-FIBROGENIC PROCESSES AND ITS REVERSAL UNIVERSIDAD NACIONAL AUTONOMA DE MEXICO (MX) 2016-05-05 US disclosed
US-20160120894-A1 USE OF ADENOSINE ASPARTATE IN THE DIFFERENTIAL ACTIVATION OF MACROPHAGES IN INFLAMMATORY-FIBROGENIC PROCESSES AND ITS REVERSAL UNIVERSIDAD NACIONAL AUTONOMA DE MEXICO (MX) 2016-05-05 US disclosed
WO-2014189349-A1 USE OF ADENOSINE ASPARTATE IN THE DIFFERENTIAL ACTIVATION OF MACROPHAGES IN INFLAMMATORY-FIBROGENIC PROCESSES AND THE REVERSION THEREOF Universidad Nacional Autónoma de México (MX) 2014-11-27 WO disclosed
WO-2014189349-A1 USE OF ADENOSINE ASPARTATE IN THE DIFFERENTIAL ACTIVATION OF MACROPHAGES IN INFLAMMATORY-FIBROGENIC PROCESSES AND THE REVERSION THEREOF Universidad Nacional Autónoma de México (MX) 2014-11-27 WO disclosed
US-8507459-B2 Use of adenosine aspartate for the preparation of pharmaceutical products for the treatment of liver cancer UNIVERSIDAD NACIONAL AUTONNOMA DE MEXICO (MX) 2013-08-13 US disclosed
US-8507459-B2 Use of adenosine aspartate for the preparation of pharmaceutical products for the treatment of liver cancer UNIVERSIDAD NACIONAL AUTONNOMA DE MEXICO (MX) 2013-08-13 US disclosed
US-8507459-B2 Use of adenosine aspartate for the preparation of pharmaceutical products for the treatment of liver cancer UNIVERSIDAD NACIONAL AUTONNOMA DE MEXICO (MX) 2013-08-13 US disclosed
US-20110105425-A1 USE OF ADENOSINE ASPARTATE FOR THE PREPARATION OF PHARMACEUTICAL PRODUCTS FOR THE TREATMENT OF LIVER CANCER UNIVERSIDAD NACIONAL AUTONOMA DE MEXICO (MX) 2011-05-05 US disclosed
US-20110105425-A1 USE OF ADENOSINE ASPARTATE FOR THE PREPARATION OF PHARMACEUTICAL PRODUCTS FOR THE TREATMENT OF LIVER CANCER UNIVERSIDAD NACIONAL AUTONOMA DE MEXICO (MX) 2011-05-05 US disclosed
EP-2186519-A4 USE OF ADENOSINE ASPARTATE FOR THE PREPARATION OF PHARMACEUTICAL PRODUCTS FOR THE TREATMENT OF LIVER CANCER UNIV MEXICO NACIONAL AUTONOMA (MX) 2010-09-01 EP disclosed
EP-2186519-A1 USE OF ADENOSINE ASPARTATE FOR THE PREPARATION OF PHARMACEUTICAL PRODUCTS FOR THE TREATMENT OF LIVER CANCER UNIVERSIDAD NACIONAL AUTONOMA DE MEXICO (MX) 2010-05-19 EP disclosed
EP-2186519-A1 USE OF ADENOSINE ASPARTATE FOR THE PREPARATION OF PHARMACEUTICAL PRODUCTS FOR THE TREATMENT OF LIVER CANCER UNIVERSIDAD NACIONAL AUTONOMA DE MEXICO (MX) 2010-05-19 EP disclosed
EP-2186519-A1 USE OF ADENOSINE ASPARTATE FOR THE PREPARATION OF PHARMACEUTICAL PRODUCTS FOR THE TREATMENT OF LIVER CANCER UNIVERSIDAD NACIONAL AUTONOMA DE MEXICO (MX) 2010-05-19 EP disclosed
WO-2009031876-A1 USE OF ADENOSINE ASPARTATE FOR THE PREPARATION OF PHARMACEUTICAL PRODUCTS FOR THE TREATMENT OF LIVER CANCER UNIVERSIDAD NACIONAL AUTONOMA DE MEXICO (MX) 2009-03-12 WO disclosed
WO-2009031876-A1 USE OF ADENOSINE ASPARTATE FOR THE PREPARATION OF PHARMACEUTICAL PRODUCTS FOR THE TREATMENT OF LIVER CANCER UNIVERSIDAD NACIONAL AUTONOMA DE MEXICO (MX) 2009-03-12 WO disclosed